Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment.

Pham TN, Lin DM, Mulrooney-Cousins PM, Churchill ND, Kowala-Piaskowska A, Mozer-Lisewska I, Machaj A, Pazgan-Simon M, Zalewska M, Simon K, King D, Reddy SB, Michalak TI.

J Med Virol. 2013 Mar;85(3):441-8. doi: 10.1002/jmv.23481. Epub 2012 Dec 21.

PMID:
23280583
3.

Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin.

Par G, Szereday L, Berki T, Palinkas L, Halasz M, Miseta A, Hegedus G, Szekeres-Bartho J, Vincze A, Hunyady B, Par A.

PLoS One. 2013 Jul 9;8(7):e67770. doi: 10.1371/journal.pone.0067770. Print 2013.

4.

Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).

Halfon P, Pérusat S, Bourlière M, Bronowicki JP, Trimoulet P, Benhamou Y, Leroy V, Marcellin P, Foucher J, Penaranda G, Chêne G, Couzigou P; ANRS HC16 GAMMATRI Study Group.

J Med Virol. 2010 Dec;82(12):2027-31. doi: 10.1002/jmv.21909.

PMID:
20981789
5.
6.

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?

Gonçales FL Jr, Moma CA, Vigani AG, Angerami AF, Gonçales ES, Tozzo R, Pavan MH, Gonçales NS.

BMC Infect Dis. 2010 Jul 20;10:212. doi: 10.1186/1471-2334-10-212.

7.

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.

Teuber G, Berg T, Hoffmann RM, Leifeld L, Lafrenz M, Spengler U, Pape GR, Hopf U, Zeuzem S.

Digestion. 2000;61(2):90-7.

PMID:
10705172
8.

Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin.

Deltenre P, Corouge M, Canva V, Castel H, Wartel F, Dharancy S, Louvet A, Lazrek M, Moreno C, Henrion J, Mathurin P.

J Hepatol. 2011 Nov;55(5):989-95. doi: 10.1016/j.jhep.2011.02.014. Epub 2011 Feb 25.

PMID:
21354445
9.

Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.

Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F; SMIEC II Investigators.

Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7. doi: 10.1097/MEG.0b013e3282f5196c.

PMID:
18679072
10.

Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder.

Di Bisceglie AM, Fan X, Chambers T, Strinko J.

J Med Virol. 2006 Apr;78(4):446-51.

PMID:
16566033
11.

Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.

Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T.

AIDS. 2004 Jan 2;18(1):75-9.

PMID:
15090832
12.

PKR gene expression and response to pegylated interferon plus ribavirin therapy in chronic hepatitis C.

Gerotto M, Dal Pero F, Bortoletto G, Realdon S, Ferrari A, Boccato S, Alberti A.

Antivir Ther. 2004 Oct;9(5):763-70.

PMID:
15535414
13.

Double-Filtration Plasmapheresis plus Interferon-β for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy.

Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Kim KI, Sasase N, Kimura N, Sasatani K, Konishi E, Hasegawa Y, Fujinami A, Ohta M, El-Shamy A, Tanaka Y, Sugano M, Sakashita M, Nakamura A, Tsuchida S, Makino T, Kawada T, Nakajima T, Morikawa T, Muramatsu A, Kasugai H, Hotta H, Kudo M.

Digestion. 2011;84 Suppl 1:10-6. doi: 10.1159/000333209. Epub 2011 Dec 2.

PMID:
22156480
14.

[Immunology of HCV infection: the causes of impaired cellular immune response and the effect of antiviral treatment].

Pár G, Berki T, Pálinkás L, Balogh P, Szereday L, Halász M, Szekeres-Barthó J, Miseta A, Hegedus G, Mózsik G, Hunyady B, Pár A.

Orv Hetil. 2006 Apr 2;147(13):591-600. Hungarian.

PMID:
16623441
15.

Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.

Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, Shebl FM, Amer AM, Butt MT, Yakoob R, John A, Al Mohanadi M, Al Khinji MA.

J Viral Hepat. 2008 Aug;15(8):591-9. doi: 10.1111/j.1365-2893.2008.00988.x. Epub 2008 May 14.

PMID:
18482284
16.

Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.

Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.

New Microbiol. 2005 Jan;28(1):13-21.

PMID:
15782622
17.
18.

Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes.

Berenguer M, Ortíz-Cantó C, Abellán JJ, Aguilera V, Rubín A, Prieto M, López-Labrador FX.

J Clin Virol. 2012 Mar;53(3):231-8. doi: 10.1016/j.jcv.2011.12.005. Epub 2012 Jan 4.

PMID:
22222052
19.

Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up.

Knolle PA, Kremp S, Höhler T, Krummenauer F, Schirmacher P, Gerken G.

J Viral Hepat. 1998 Nov;5(6):399-406.

PMID:
9857349
20.

Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.

Kondo Y, Ueno Y, Ninomiya M, Tamai K, Tanaka Y, Inoue J, Kakazu E, Kobayashi K, Kimura O, Miura M, Yamamoto T, Kobayashi T, Igarashi T, Shimosegawa T.

J Gastroenterol. 2012 Dec;47(12):1323-35. doi: 10.1007/s00535-012-0596-x. Epub 2012 May 16.

PMID:
22588246
Items per page

Supplemental Content

Write to the Help Desk